On Wednesday, bluebird bio, Inc. (BLUE) announced the appointment of James Sterling as Chief Financial Officer. Sterling will assume the role on June 10, succeeding Chris Krawtschuk, who has served as bluebird bio's CFO since 2022.
Most recently, Sterling held the position of Chief Financial Officer at Renalytix plc, a diagnostics company specializing in the clinical management of kidney disease.
In pre-market activity on Nasdaq, bluebird bio's shares are trading at $0.92, down 2.14%.
